AstraZeneca’s Fasenra Approved in EU for Treating Rare Vasculitis, Offering New Hope for EGPA Patients
(IN BRIEF) AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare and severe form of vasculitis. The approval follows positive results from the MANDARA Phase III trial, which showed nearly 60% of patients achieving remission and 41% successfully discontinuing oral corticosteroids. The new indication offers a much-needed treatment option for EGPA patients, complementing Fasenra’s established use in severe eosinophilic asthma. The medication’s safety profile remains consistent with previous data, and it provides a once-monthly injection for ease of use.
(PRESS RELEASE) CAMBRIDGE, 28-Oct-2024 — /EuropaWire/ — AstraZeneca’s Fasenra (benralizumab) has received approval from the European Union (EU) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated form of vasculitis that can lead to severe organ damage and potentially fatal outcomes if left untreated.
The European Commission’s decision follows a positive recommendation from the Committee for Medicinal Products for Human Use, based on data from the MANDARA Phase III clinical trial. The trial, published in The New England Journal of Medicine, is notable for being the first head-to-head non-inferiority study comparing biologics for EGPA treatment. Patients in the study were randomly assigned to receive either a single 30 mg injection of Fasenra or three 100 mg doses of mepolizumab every four weeks.
Results from the MANDARA trial demonstrated that nearly 60% of patients treated with Fasenra achieved disease remission, a rate similar to that observed in the mepolizumab group. Additionally, 41% of those on Fasenra successfully discontinued oral corticosteroids, compared to 26% in the comparator group, highlighting a significant reduction in corticosteroid dependence.
Bernhard Hellmich, Principal Investigator of the MANDARA trial and a leading expert in internal medicine and rheumatology, emphasized the importance of this new option: “EGPA patients face severe symptoms and the risk of life-threatening complications. The approval of Fasenra provides a crucial treatment option that targets eosinophilic inflammation directly, potentially leading to more patients achieving remission and reducing their reliance on corticosteroids, which carry substantial long-term risks.”
Ruud Dobber, Executive Vice President of AstraZeneca’s BioPharmaceuticals Business Unit, expressed optimism about the approval: “This marks a significant step forward for EGPA patients in Europe. Fasenra’s once-monthly injection provides a convenient and effective treatment option for a condition that is difficult to manage. With Fasenra already established as a leading therapy for severe eosinophilic asthma, we are pleased to extend this option to those with EGPA.”
The safety profile of Fasenra in the MANDARA study aligned with its known tolerability, offering reassurance for its use in this new indication. EGPA often coexists with severe eosinophilic asthma (SEA), making Fasenra a valuable option for patients with overlapping conditions. Fasenra is now the second biologic available for EGPA treatment, following its earlier approval in the United States in September.
Already authorized in over 80 countries as a treatment for SEA, including the US, Japan, and China, Fasenra’s new EU approval for EGPA offers hope to patients facing this challenging and rare disease.
Notes
Eosinophilic granulomatosis with polyangiitis
EGPA, formerly known as Churg-Strauss Syndrome, is a rare, immune-mediated inflammatory disease that is caused by inflammation of small to medium-sized blood vessels.1,2 It is estimated that 118,000 people throughout the world live with EGPA.14 EGPA can result in damage to multiple organs, including lungs, upper airway, skin, heart, gastrointestinal tract and nerves.2 The most common symptoms and signs include extreme fatigue, weight loss, muscle and joint pain, rashes, nerve pain, sinus and nasal symptoms, and shortness of breath.2,15 Without treatment, the disease may be fatal.2 Almost half (47%) of patients do not achieve remission with current treatments.15
There are limited treatment options for EGPA. Patients are often treated with chronic high-dose OCS and experience recurrent relapses when attempting to taper off OCS.16,17
MANDARA
MANDARA was a Phase III, randomised, double-blinded, active-controlled trial, which compared the efficacy and safety of Fasenra to mepolizumab in adult patients with relapsing or refractory EGPA.4 In the trial, 140 patients were randomised 1:1 to receive either a single 30mg subcutaneous injection of Fasenra or three separate 100mg subcutaneous injections of the active comparator every four weeks.3
The primary endpoint was the proportion of patients who were in remission at both weeks 36 and 48.4 Remission is defined as Birmingham Vasculitis Activity Score (BVAS)=0 and OCS dose less than or equal to 4 mg/day.4 A secondary endpoint was the proportion of patients who were able to fully taper off OCS at weeks 48 through 52.3 The primary statistical analysis was to demonstrate non-inferiority of Fasenra versus mepolizumab based on the primary endpoint.3
Fasenra
Fasenra (benralizumab) is currently approved in more than 80 countries, including the US, Japan, EU and China.9-12 Fasenra has been prescribed to over 130,000 patients globally.18
Fasenra is in development for other diseases including chronic obstructive pulmonary disease and hypereosinophilic syndrome.19,20
Fasenra was developed by AstraZeneca and is in-licensed from BioWa, Inc., a wholly owned subsidiary of Kyowa Kirin Co., Ltd., Japan.
AstraZeneca in Respiratory & Immunology
Respiratory & Immunology, part of AstraZeneca BioPharmaceuticals, is a key disease area and growth driver to the Company.
AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. The Company is committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets. Our ambition is to deliver life-changing medicines that help eliminate COPD as a leading cause of death, eliminate asthma attacks and achieve clinical remission in immune-mediated diseases.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
References
1. Furuta S, et al. Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019;68:430-436.
2. American Partnership for Eosinophilic Disorders. Eosinophilic Granulomatosis with Polyangiitis (EGPA). Available at: https://apfed.org/about-ead/eosinophilic-granulomatosis-with-polyangiitis/. [Last accessed: October 2024].
3. Wechsler ME, et al. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2024;390(10):911-921.
4. Clinicaltrials.gov. Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (MANDARA). Available at: https://classic.clinicaltrials.gov/ct2/show/NCT04157348. [Last accessed: October 2024].
5. Mepolizumab US prescribing information. Available from: https://www.fda.gov/files/drugs/published/125526-Mepolizumab-Clinical-PREA.pdf [Last accessed: October 2024].
6. AstraZeneca plc. MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with Fasenra. Available at: https://www.astrazeneca.com/media-centre/medical-releases/mandara-phase-iii-data-published-new-england-journal-medicine-show-remission-achievable-goal-eosinophilic-granulomatosis-polyangiitis-egpa-fasenra.html. [Last accessed: October 2024].
7. Cottin V, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Eur Respir J. 2016;48:1429-1441.
8. Heaney L et al. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. Chest. 2021 Sep;160(3):814-830.
9. AstraZeneca news release. Available at: https://www.astrazeneca.com/media-centre/press-releases/2019/fasenra-approved-in-the-us-for-self-administration-in-a-new-pre-filled-auto-injector-the-fasenra-pen-04102019.html#. [Last accessed: October 2024].
10. AstraZeneca news release. Available at: https://www.astrazeneca.com/media-centre/press-releases/2019/fasenra-receives-positive-eu-chmp-opinion-for-self-administration-and-the-new-fasenra-pen-a-pre-filled-single-use-auto-injector-01072019.html#. [Last accessed: October 2024].
11. AstraZeneca Annual Report 2023. Available at: https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2023/pdf/AstraZeneca_AR_2023.pdf. [Last accessed: October 2024].
12. AstraZeneca news release. Available at: https:// www.astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-china-for-the-treatment-of-severe-eosinophilic-asthma.html. [Last accessed: October 2024].
13. Fasenra (benralizumab) US prescribing information; September 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761070s021lbl.pdf [Last accessed: October 2024].
14. AstraZeneca Data on file. 2024. REF- 244520.
15. Wechsler ME, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017:376;1921-1932.
16. Baldini C, et al. Clinical Manifestations and Treatment of Churg-Strauss Syndrome. Rheum Dis Clin N Am. 2010;36:527–543.
17. Bell CF, et al. Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States. J Manag Care Spec Pharm. 2021;27(9):1249-1259.
18. AstraZeneca data on file. 2024. REF-235794.
19. Clinicaltrials.gov. Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations (RESOLUTE). Available from: https://clinicaltrials.gov/ct2/show/NCT04053634 [Last accessed: October 2024].
20. Clinicaltrials.gov. A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (NATRON). Available from: https://clinicaltrials.gov/ct2/show/NCT04191304 [Last accessed: October 2024].
Media Contact:
Tel: +44 (0)1223 344 800
email: global-mediateam@astrazeneca.com
SOURCE: AstraZeneca
MORE ON ASTRAZENECA, ETC.:
EDITOR’S PICK:
Digi Communications N.V. announces that the Company’s Portuguese subsidiary finalised the transaction with LORCA JVCO Limited
Digi Communications N.V. announces that the Portuguese Competition Authority has granted clearance for the share purchase agreement concluded by the Company’s subsidiary in Portugal
OMRON Healthcare introduceert nieuwe bloeddrukmeters met AI-aangedreven AFib-detectietechnologie; lancering in Europa september 2024
OMRON Healthcare dévoile de nouveaux tensiomètres dotés d’une technologie de détection de la fibrillation auriculaire alimentée par l’IA, lancés en Europe en septembre 2024
OMRON Healthcare presenta i nuovi misuratori della pressione sanguigna con tecnologia di rilevamento della fibrillazione atriale (AFib) basata sull’IA, in arrivo in Europa a settembre 2024
OMRON Healthcare presenta los nuevos tensiómetros con tecnología de detección de fibrilación auricular (FA) e inteligencia artificial (IA), que se lanzarán en Europa en septiembre de 2024
Alegerile din Moldova din 2024: O Bătălie pentru Democrație Împotriva Dezinformării
Northcrest Developments launches design competition to reimagine 2-km former airport Runway into a vibrant pedestrianized corridor, shaping a new era of placemaking on an international scale
The Road to Sustainable Electric Motors for EVs: IDTechEx Analyzes Key Factors
Infrared Technology Breakthroughs Paving the Way for a US$500 Million Market, Says IDTechEx Report
MegaFair Revolutionizes the iGaming Industry with Skill-Based Games
European Commission Evaluates Poland’s Media Adherence to the Right to be Forgotten
Global Race for Autonomous Trucks: Europe a Critical Region Transport Transformation
Digi Communications N.V. confirms the full redemption of €450,000,000 Senior Secured Notes
AT&T Obtiene Sentencia Contra Grupo Salinas Telecom, Propiedad de Ricardo Salinas, Sus Abogados se Retiran Mientras Él Mueve Activos Fuera de EE.UU. para Evitar Pagar la Sentencia
Global Outlook for the Challenging Autonomous Bus and Roboshuttle Markets
Evolving Brain-Computer Interface Market More Than Just Elon Musk’s Neuralink, Reports IDTechEx
Latin Trails Wraps Up a Successful 3rd Quarter with Prestigious LATA Sustainability Award and Expands Conservation Initiatives ↗️
Astor Asset Management 3 Ltd leitet Untersuchung für potenzielle Sammelklage gegen Ricardo Benjamín Salinas Pliego von Grupo ELEKTRA wegen Marktmanipulation und Wertpapierbetrug ein
Digi Communications N.V. announces that the Company’s Romanian subsidiary exercised its right to redeem the Senior Secured Notes due in 2025 in principal amount of €450,000,000
Astor Asset Management 3 Ltd Inicia Investigación de Demanda Colectiva Contra Ricardo Benjamín Salinas Pliego de Grupo ELEKTRA por Manipulación de Acciones y Fraude en Valores
Astor Asset Management 3 Ltd Initiating Class Action Lawsuit Inquiry Against Ricardo Benjamín Salinas Pliego of Grupo ELEKTRA for Stock Manipulation & Securities Fraud
Digi Communications N.V. announced that its Spanish subsidiary, Digi Spain Telecom S.L.U., has completed the first stage of selling a Fibre-to-the-Home (FTTH) network in 12 Spanish provinces
Natural Cotton Color lancia la collezione “Calunga” a Milano
Astor Asset Management 3 Ltd: Salinas Pliego Incumple Préstamo de $110 Millones USD y Viola Regulaciones Mexicanas
Astor Asset Management 3 Ltd: Salinas Pliego Verstößt gegen Darlehensvertrag über 110 Mio. USD und Mexikanische Wertpapiergesetze
ChargeEuropa zamyka rundę finansowania, której przewodził fundusz Shift4Good tym samym dokonując historycznej francuskiej inwestycji w polski sektor elektromobilności
Strengthening EU Protections: Robert Szustkowski calls for safeguarding EU citizens’ rights to dignity
Digi Communications NV announces the release of H1 2024 Financial Results
Digi Communications N.V. announces that conditional stock options were granted to a director of the Company’s Romanian Subsidiary
Digi Communications N.V. announces Investors Call for the presentation of the H1 2024 Financial Results
Digi Communications N.V. announces the conclusion of a share purchase agreement by its subsidiary in Portugal
Digi Communications N.V. Announces Rating Assigned by Fitch Ratings to Digi Communications N.V.
Digi Communications N.V. announces significant agreements concluded by the Company’s subsidiaries in Spain
SGW Global Appoints Telcomdis as the Official European Distributor for Motorola Nursery and Motorola Sound Products
Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2023 financial year
Digi Communications N.V. announces the exercise of conditional share options by the executive directors of the Company, for the year 2023, as approved by the Company’s Ordinary General Shareholders’ Meetings from 18th May 2021 and 28th December 2022
Digi Communications N.V. announces the granting of conditional stock options to Executive Directors of the Company based on the general shareholders’ meeting approval from 25 June 2024
Digi Communications N.V. announces the OGMS resolutions and the availability of the approved 2023 Annual Report
Czech Composer Tatiana Mikova Presents Her String Quartet ‘In Modo Lidico’ at Carnegie Hall
SWIFTT: A Copernicus-based forest management tool to map, mitigate, and prevent the main threats to EU forests
WickedBet Unveils Exciting Euro 2024 Promotion with Boosted Odds
Museum of Unrest: a new space for activism, art and design
Digi Communications N.V. announces the conclusion of a Senior Facility Agreement by companies within Digi Group
Digi Communications N.V. announces the agreements concluded by Digi Romania (formerly named RCS & RDS S.A.), the Romanian subsidiary of the Company
Green Light for Henri Hotel, Restaurants and Shops in the “Alter Fischereihafen” (Old Fishing Port) in Cuxhaven, opening Summer 2026
Digi Communications N.V. reports consolidated revenues and other income of EUR 447 million, adjusted EBITDA (excluding IFRS 16) of EUR 140 million for Q1 2024
Digi Communications announces the conclusion of Facilities Agreements by companies from Digi Group
Digi Communications N.V. Announces the convocation of the Company’s general shareholders meeting for 25 June 2024 for the approval of, among others, the 2023 Annual Report
Digi Communications NV announces Investors Call for the presentation of the Q1 2024 Financial Results
Digi Communications intends to propose to shareholders the distribution of dividends for the fiscal year 2023 at the upcoming General Meeting of Shareholders, which shall take place in June 2024
Digi Communications N.V. announces the availability of the Romanian version of the 2023 Annual Report
Digi Communications N.V. announces the availability of the 2023 Annual Report
International Airlines Group adopts Airline Economics by Skailark ↗️
BevZero Spain Enhances Sustainability Efforts with Installation of Solar Panels at Production Facility
Digi Communications N.V. announces share transaction made by an Executive Director of the Company with class B shares
BevZero South Africa Achieves FSSC 22000 Food Safety Certification
Digi Communications N.V.: Digi Spain Enters Agreement to Sell FTTH Network to International Investors for Up to EUR 750 Million
Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics
driveMybox continues its international expansion: Hungary as a new strategic location
Monesave introduces Socialised budgeting: Meet the app quietly revolutionising how users budget
Digi Communications NV announces the release of the 2023 Preliminary Financial Results
Digi Communications NV announces Investors Call for the presentation of the 2023 Preliminary Financial Results
Lensa, един от най-ценените търговци на оптика в Румъния, пристига в България. Първият шоурум е открит в София
Criando o futuro: desenvolvimento da AENO no mercado de consumo em Portugal
Digi Communications N.V. Announces the release of the Financial Calendar for 2024
Customer Data Platform Industry Attracts New Participants: CDP Institute Report
eCarsTrade annonce Dirk Van Roost au poste de Directeur Administratif et Financier: une décision stratégique pour la croissance à venir
BevZero Announces Strategic Partnership with TOMSA Desil to Distribute equipment for sustainability in the wine industry, as well as the development of Next-Gen Dealcoholization technology
Digi Communications N.V. announces share transaction made by a Non-Executive Director of the Company with class B shares
Digi Spain Telecom, the subsidiary of Digi Communications NV in Spain, has concluded a spectrum transfer agreement for the purchase of spectrum licenses
Эксперт по торговле акциями Сергей Левин запускает онлайн-мастер-класс по торговле сырьевыми товарами и хеджированию
Digi Communications N.V. announces the conclusion by Company’s Portuguese subsidiary of a framework agreement for spectrum usage rights
North Texas Couple Completes Dream Purchase of Ouray’s Iconic Beaumont Hotel
Предприниматель и филантроп Михаил Пелег подчеркнул важность саммита ООН по Целям устойчивого развития 2023 года в Нью-Йорке
Digi Communications NV announces the release of the Q3 2023 Financial Results
IQ Biozoom Innovates Non-Invasive Self-Testing, Empowering People to Self-Monitor with Laboratory Precision at Home
BevZero Introduces Energy Saving Tank Insulation System to Europe under name “BevClad”
Motorvision Group reduces localization costs using AI dubbing thanks to partnering with Dubformer
Digi Communications NV Announces Investors Call for the Q3 2023 Financial Results
Jifiti Granted Electronic Money Institution (EMI) License in Europe
Предприниматель Михаил Пелег выступил в защиту образования и грамотности на мероприятии ЮНЕСКО, посвящённом Международному дню грамотности
VRG Components Welcomes New Austrian Independent Agent
Digi Communications N.V. announces that Digi Spain Telecom S.L.U., its subsidiary in Spain, and abrdn plc have completed the first investment within the transaction having as subject matter the financing of the roll out of a Fibre-to-the-Home (“FTTH”) network in Andalusia, Spain
Продюсер Михаил Пелег, как сообщается, работает над новым сериалом с участием крупной голливудской актрисы
Double digit growth in global hospitality industry for Q4 2023
ITC Deploys Traffic Management Solution in Peachtree Corners, Launches into United States Market
Cyviz onthult nieuwe TEMPEST dynamische controlekamer in Benelux, Nederland
EU-Funded CommuniCity Launches its Second Open Call
Astrologia pode dar pistas sobre a separação de Sophie Turner e Joe Jonas
La astrología puede señalar las razones de la separación de Sophie Turner y Joe Jonas
Empowering Europe against infectious diseases: innovative framework to tackle climate-driven health risks
Montachem International Enters Compostable Materials Market with Seaweed Resins Company Loliware
Digi Communications N.V. announces that its Belgian affiliated companies are moving ahead with their operations
Digi Communications N.V. announces the exercise of conditional share options by an executive director of the Company, for the year 2022, as approved by the Company’s Ordinary General Shareholders’ Meeting from 18 May 2021
Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2022 financial year
Digi Communications N.V. announces the availability of the 2022 Annual Report
Digi Communications N.V. announces the general shareholders’ meeting resolutions from 18 August 2023 approving amongst others, the 2022 Annual Accounts
Русские эмигранты усиливают призывы «Я хочу, чтобы вы жили» через искусство
BevZero Introduces State-of-the-Art Mobile Flash Pasteurization Unit to Enhance Non-Alcoholic Beverage Stability at South Africa Facility
Russian Emigrés Amplify Pleas of “I Want You to Live” through Art
Digi Communications NV announces the release of H1 2023 Financial Results
Digi Communications NV Announces Investors Call for the H1 2023 Financial Results
Digi Communications N.V. announces the convocation of the Company’s general shareholders meeting for 18 August 2023 for the approval of, among others, the 2022 Annual Report
“Art Is Our Weapon”: Artists in Exile Deploy Their Talents in Support of Peace, Justice for Ukraine
Digi Communications N.V. announces the availability of the 2022 Annual Financial Report
“AmsEindShuttle” nuevo servicio de transporte que conecta el aeropuerto de Eindhoven y Ámsterdam
Un nuovo servizio navetta “AmsEindShuttle” collega l’aeroporto di Eindhoven ad Amsterdam
Digi Communications N.V. announces the conclusion of an amendment agreement to the Facility Agreement dated 26 July 2021, by the Company’s Spanish subsidiary
Digi Communications N.V. announces an amendment of the Company’s 2023 financial calendar
iGulu F1: Brewing Evolution Unleashed
Почему интерактивная «Карта мира» собрала ключевые антивоенные сообщества россиян по всему миру и становится для них важнейшим инструментом
Hajj Minister meets EU ambassadors to Saudi Arabia
Online Organizing Platform “Map of Peace” Emerges as Key Tool for Diaspora Activists
Digi Communications N.V. announces that conditional stock options were granted to executive directors of the Company based on the general shareholders’ meeting approval from 18 May 2021
Digi Communications N.V. announces the release of the Q1 2023 financial results
AMBROSIA – A MULTIPLEXED PLASMO-PHOTONIC BIOSENSING PLATFORM FOR RAPID AND INTELLIGENT SEPSIS DIAGNOSIS AT THE POINT-OF-CARE
Digi Communications NV announces Investors Call for the Q1 2023 Financial Results presentation
Digi Communications N.V. announces the amendment of the Company’s 2023 financial calendar
Digi Communications N.V. announces the conclusion of two Facilities Agreements by the Company’s Romanian subsidiary
Digi Communications N.V. announces the conclusion of a Senior Facility Agreement by the Company’s Romanian subsidiary
Patients as Partners Europe Returns to London and Announces Agenda Highlights
GRETE PROJECT RESULTS PRESENTED TO TEXTILE INDUSTRY STAKEHOLDERS AT INTERNATIONAL CELLULOSE FIBRES CONFERENCE
Digi Communications N.V. announces Digi Spain Telecom S.L.U., its subsidiary in Spain, entered into an investment agreement with abrdn to finance the roll out of a Fibre-to-the-Home (FTTH) network in Andalusia, Spain
XSpline SPA / University of Linz (Austria): the first patient has been enrolled in the international multicenter clinical study for the Cardiac Resynchronization Therapy DeliveRy guided by non-Invasive electrical and VEnous anatomy assessment (CRT-DRIVE)
Franklin Junction Expands Host Kitchen® Network To Europe with Digital Food Hall Pioneer Casper
Unihertz a dévoilé un nouveau smartphone distinctif, Luna, au MWC 2023 de Barcelone
Unihertz Brachte ein Neues, Markantes Smartphone, Luna, auf dem MWC 2023 in Barcelona
Editor’s pick archive….
Source link : http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=671facdbbd2043c2a6c6cc10d4ad0758&url=https%3A%2F%2Fnews.europawire.eu%2Fastrazenecas-fasenra-approved-in-eu-for-treating-rare-vasculitis-offering-new-hope-for-egpa-patients%2Feu-press-release%2F2024%2F10%2F28%2F15%2F47%2F34%2F142887%2F&c=2890330255252927343&mkt=de-de
Author :
Publish date : 2024-10-28 08:20:00
Copyright for syndicated content belongs to the linked Source.